Skip to main content
SpringerLink
Log in

Medulloblastoma

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Medulloblastomas, primitive neuroectodermal tumors of the cerebellum, comprise 20% of all pediatric brain tumors and are the most common solid neoplasm in children. Primitive neuroectodermal tumors are believed to arise from cerebellar granule cell precursors. Occasionally, medulloblastoma occurs in children with genetically linked disorders, such as Turcot’s syndrome or Gorlin’s syndrome, which is also called basal cell nevus syndrome. Several genes have been implicated in the development of medulloblastoma in children, including Patched-1 and Smoothened. The protein products of these genes function within the sonic hedgehog molecular signaling pathways, which are important in neural development and disease. Through analysis of several well-designed multi-institutional trials, much has been learned about the clinical factors that influence outcome in children with medulloblastomas. Age younger than 3 years, bulky residual disease postoperatively, and metastasis constitute adverse prognostic features and indicate patients who are considered “high risk” for recurrence with standard therapy using 3600 cGy craniospinal radiation in conjunction with a posterior fossa dose of 5400 cGy. Patients lacking these features are considered “standard risk.” Chemotherapeutic trials have been developed to assess the safety and efficacy of various multi-agent therapies to improve the poor results of high-risk patients and to allow reduction in the dose of radiation needed to cure standard-risk patients, which may allow a decrease in late cognitive sequelae. Currently, it is policy to evaluate all children with posterior fossa tumors characteristic of medulloblastoma with preoperative, staging neuroimaging studies of the craniospinal axis. Surgical resection is undertaken with the goal of gross total resection. Postoperative neuroimaging studies are compared with preoperative studies to determine the amount of residual disease. Cerebrospinal fluid is obtained from a lumbar puncture done at the conclusion of the surgical resection or 2 weeks after surgery in order to determine microscopic leptomeningeal spread. Children with tumor histopathology consistent with medulloblastoma are enrolled, when possible, in open clinical trials. Chemotherapy and radiation are given as per protocol. The goal of current treatment approaches is to tailor therapy based on clinical risk factors, with intensification of treatment for children with high-risk disease and reduction of radiation therapy for those with standard-risk disease. Evaluation of biologic predictors of outcome, which may further refine treatment stratification, is in progress.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Morris JH: The nervous system. In Robbins Pathologic Basis of Disease. Edited by Cotran RS, Kumar V, Collins T. Philadelphia: WB Saunders Company; 1999: 1419–1420.

    Google Scholar 

  2. Goussia AC, Bruner JM, Kyritsis, et al.: Cytogenetic and molecular genetic abnormalities in primitive neuroectodermal tumors of the central nervous system. Anticancer Res 2000, 20:65–73. A comprehensive review and summary of the multiple genetic abnormalities found in primitive neuroectodermal tumors. Discussion about the prognostic significance of various markers ensues.

    PubMed  CAS  Google Scholar 

  3. Vorechovsky I, Tingby O, Hartman M, et al.: Somatic mutations in the human homologue of Drosophila patched in primitive neuroectodermal tumors. Oncogene 1997, 15:361–166.

    Article  PubMed  CAS  Google Scholar 

  4. Wolter M, Reifenberger J, Sommer C, et al.: Mutations of the human homologue of the Drosophila segment polarity gene patched (PTCH) in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1997, 57:2581–2585.

    PubMed  CAS  Google Scholar 

  5. Lam CW, Xie J, To KF, et al.: A frequent activated smoothened mutation in sporadic basal cell carcinomas. Oncogene 1999, 18:833–866.

    Article  PubMed  CAS  Google Scholar 

  6. Xie J, Murone M, Luoh SM, et al.: Activating smoothened mutations in sporadic basal cell carcinoma. Nature 1998, 391:90–92.

    Article  PubMed  CAS  Google Scholar 

  7. Taipale J, Baechy PA: The hedgehog and wnt signaling pathways in cancer. Nature 2001, 411:349–354.

    Article  PubMed  CAS  Google Scholar 

  8. Goodrich LV, Scott MP: Hedgehog and patched in neural development and disease. Neuron 1998, 21:1243–1257.

    Article  PubMed  CAS  Google Scholar 

  9. Rorke L: The cerebellar medulloblastoma and its relationship to primitive neuroectodermal tumors. J Neuropathol Exp Neurol 1983, 42:1–15.

    PubMed  CAS  Google Scholar 

  10. Pomeroy SL, Tamayo P, Gaasenbeek M, et al.: Prediction of central nervous system embryonal tumor outcome based on gene expression. Nature 2002, 415:436–442. This is a translational science paper that describes the DNA microarray analysis of 99 MB specimens. The expression patterns allowed differentiation of supratentorial PNET from MB. Desmoplastic MB expression profiles also differed significantly from that of true MB. Evidence supporting the origination of MB from cerebellar granule cells was also detailed. Prognostic significance of specific expression patterns was explored.

    Article  PubMed  CAS  Google Scholar 

  11. Laurent JP, Chang CH, Cohen ME: A classification system for primitive neuroectodermal tumors (medulloblastoma) of the posterior fossa. Cancer 1985, 56:1807–1809.

    Article  PubMed  CAS  Google Scholar 

  12. Goldstein AM, Yuen J, Tucker MA: Second cancers after medulloblastoma: population based results from the United States and Sweden. Cancer Causes Control 1997, 8:865–871.

    Article  PubMed  CAS  Google Scholar 

  13. Jenkin D: Long-term survival of children with brain tumors. Oncology 1996, 10:715–719.

    PubMed  CAS  Google Scholar 

  14. Minn AY, Pollack BH, Garzarella L, et al.: Surveillance neuroimaging to detect relapse in childhood brain tumors: a Pediatric Oncology Group study. J Clinical Oncol 2001, 19:4135–4140. This is a good retrospective review of data from 10 Pediatric Oncology Group studies of children with malignant brain tumors. Time to relapse and presentation (clinical vs radiographic) was studied. Advocates the clinical use of surveillance neuroimaging, but also acknowledges the need for prospective studies to determine optimal timing of these studies.

    CAS  Google Scholar 

  15. Torres CF, Rebsamen S, Silber JH, et al.: Surveillance scanning of children with medulloblastoma. N Engl J Med 1994, 330:892–895.

    Article  PubMed  CAS  Google Scholar 

  16. Wilke M, Eidenschink A, Muller-Weihrich S, et al.: MR diffusion and 1H spectroscopy in a child with medulloblastoma. Acta Radiol 2001, 42:39–42.

    PubMed  CAS  Google Scholar 

  17. Michiels EM, Weiss MM, Hoovers JM, et al.: Genetic alterations in childhood medulloblastoma analyzed by comparative genomic hybridization. J Pediatr Hematol Oncol 2002, 24:205–210. A recent, translational science article describing chromosomal abnormalities detected in 15 MB specimens. All tumors analyzed demonstrated significant chromosomal aberrations.

    Article  PubMed  Google Scholar 

  18. Raffel C, Jenkins RB, Frederick L, et al.: Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997, 57:842–845.

    PubMed  CAS  Google Scholar 

  19. Calzada-Wack J, Kappler R, Schnitzbauer U, et al.: Unbalanced over-expression of the mutant allele in murine Patched mutants. Carcinogenesis 2002, 23:727–733.

    Article  PubMed  CAS  Google Scholar 

  20. Corcoran RB, Scott MP: A mouse model for medulloblastoma and basal cell nevus syndrome. J Neurooncol 2001, 53:307–318. A new mouse model, heterozygous for Patched-1, in which basal cell nevus syndrome and MB develop at high frequency.

    Article  PubMed  CAS  Google Scholar 

  21. Taylor MD, Hogg D, Liu L, et al.: Molecular cloning, genomic structure, mapping and mutational analysis of human suppressor of Fused (hsu[fu]), a candidate tumor suppressor gene for medulloblastoma/PNET on chromosome 10q24.3. Neurosurgery 2000, 47:518.

    Article  Google Scholar 

  22. Gilbertson R: Pediatric embryonic brain tumors, biological and clinical relevance of molecular genetic abnormalities. Eur J Cancer 2002, 38:675–685. An informative, in-depth review of the molecular signaling pathways involved in embryonal neuroepithelial malignancies.

    Article  PubMed  CAS  Google Scholar 

  23. Grotzer MA, Geoerger B, Janss AJ, et al.: Prognostic significance of Ki-67 (MIB-1) proliferation index in childhood primitive neuroectodermal tumors of the central nervous system. Med Pediatr Oncol 2001, 36:268–273. A single institution study comparing 78 MB specimen and their proliferation indices (PI). “Hot spot” PI define areas within a tumor where focal Ki-67 positivity is appreciated. This study determined that “hot spot” PI is an independent and significant predictor of tumor progression and death.

    Article  PubMed  CAS  Google Scholar 

  24. Grotzer MA, Hogarty MD, Janss AJ, et al.: MYC messenger RNA expression predicts survival outcome in childhood primitive neuroectodermal tumor/medulloblastoma. Clin Cancer Res 2001, 7:2425–2433. This translational paper by Grotzer et al. analyzed the expression of MYC and TrkC in 26 MB patients. Low MYC and high TrkC messenger RNA expression correlated with good outcome and progression-free survival.

    PubMed  CAS  Google Scholar 

  25. MacDonald TJ, Brown KM, LaFleur B, et al.: Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. Nat Genet 2001, 29:143–152. A single institution study that used affymetrix expression arrays to look for genes preferentially expressed in patients presenting with metastatic MB.

    Article  PubMed  CAS  Google Scholar 

  26. MacDonald TJ, Ladisch S: Antisense to integrin alpha-v inhibits growth and induces apoptosis in medulloblastoma cells. Anticancer Res 2001, 21:3785–3791. An interesting study of MB cell-line growth inhibition induced by anti-sense oligonucleotides. Anti-sense alpha-v reduced cell migration and proliferation, and caused a Go-G1 cell cycle arrest.

    PubMed  CAS  Google Scholar 

  27. Park P, Taylor MD, Squire J, et al.: Complementary deoxyribonucleic acid microarray analysis of pediatric medulloblastomas. Neurosurgery 2001, 49:546. Many more reports of this nature are likely forthcoming. Six MB specimens were analyzed using complementary DNA microarray technology. The expression of over 1200 genes was investigated.

    Article  Google Scholar 

  28. Albright AL, Wisoff JH, Zeltzer PM, et al.: Effects of medulloblastoma resections on outcome in children: a report from the Children’s Cancer Group. Neurosurgery 1996, 38:265–271,

    Article  PubMed  CAS  Google Scholar 

  29. Ater JL, van Eys J, Woo SY, et al.: MOPP chemotherapy without radiation as primary postsurgical therapy for brain tumors in infants and young children. J Neurooncology 1997, 32:243–252.

    Article  CAS  Google Scholar 

  30. Packer RJ, Sutton LN, Elterman R, et al.: Outcome for children with medulloblastoma treated with radiation and cisplatin, CCNU, and vincristine chemotherapy. J Neurosurgery 1994, 81:690–698.

    CAS  Google Scholar 

  31. Evans A, Jenkin R, Sposto R, et al.: The treatment of medulloblastoma: the results of a prospective randomized trial of RT with and without chlorethycyclohexyl nitrosurea, vincristine, and prednisone. J Neurosurg 1990, 72:572–582.

    Article  PubMed  CAS  Google Scholar 

  32. Packer RJ, Goldwein J, Nicholson HS, et al.: Treatment of children with medulloblastomas with reduceddose craniospinal radiation therapy and adjuvant chemotherapy: a Children’s Cancer Group Study. J Clin Oncol 1999, 17:2127–2136. The clinical report of the Children’s Cancer Group 9892 study. The response and 5-year progression-free survival in children with MB who were 3 to 10 years of age and in whom there was no evidence of metastases. Children were treated with reduced-dose craniospinal radiation and adjuvant chemotherapy with lomustine, vincristine and cisplatin.

    PubMed  CAS  Google Scholar 

  33. Stavrou T, Bromley CM, Nicholson HS, et al.: Prognostic Factors and secondary malignancies in childhood medulloblastoma. J Ped Hematol Oncol 2001, 23:431–436. A recent article reporting the increased risk of secondary malignancies in a cohort of 88 children with MB treated at a single institution.

    Article  CAS  Google Scholar 

  34. Mosijczuk AD, Nigro MA, Thomas PR, et al.: Pre-radiation chemotherapy in advanced medulloblastoma: a Pediatric Oncology Group pilot study. Cancer 1993, 72:2755–2762.

    Article  PubMed  CAS  Google Scholar 

  35. Fisher PG, Kadan-Lottick NS, Korones DN: Intrathecal thiotepa: reappraisal of an established therapy. J Pediatr Hematol Oncol 2002, 24:274–278.

    Article  PubMed  Google Scholar 

  36. Duffner PK, Horowitz ME, Krischer JP, et al.: Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 1993, 328:1725–1731.

    Article  PubMed  CAS  Google Scholar 

  37. Mason WP, Grovas A, Halpern S, et al.: Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J of Clinical Oncology 1998, 16:210–221.

    CAS  Google Scholar 

  38. Deutsch M, Thomas PR, Krischer J, et al.: Results of a prospective, randomized clinical trial comparing standard dose neuroaxis irradiation (3,600cGy/20) with reduced neuroaxis irradiation (2,340 cGy/13) in patients with low-stage medulloblastoma: a combined Children’s cancer Group-Pediatric Oncology Group study. Ped Neurosurgery 1996, 24:167–177.

    CAS  Google Scholar 

  39. Thomas PR, Deutsch M, Kepner JL, et al.: Low-stage medulloblastoma: final analysis of trail comparing standard dose with reduced-dose neuroaxis radiation. J Clin Oncol 2000, 18:3004–3011. A report of the 5-year follow-up results from Pediatric Oncology Group 8631 and Children’s Cancer Group 923 studies. The response differences between standard and reduced-dose craniospinal radiation were compared in patients with MB. Early risks of early relapse with lower 5-year event-free survival and overall survival were seen in children treated with reduced-dose radiation. Conclusions support the use of chemotherapy to potentially increase overall survival.

    PubMed  CAS  Google Scholar 

  40. Prados M, Edwards S, Chang S, et al.: Hyperfractionated craniospinal radiation therapy for primitive neuroectodermal tumors: results of a phase II study. Int J Radiat Oncol Biol Phys 1998, 43:279–285.

    Article  Google Scholar 

  41. Merchant TE, Happersett L, Findlay JL, et al.: Preliminary results of conformal radiation therapy for medulloblastoma. Neurooncol 1999, 1:177–187. A single institution study for conformal radiation therapy used in 14 patients. Local failure rates, hearing loss, and effect on intelligence quotient were analyzed.

    CAS  Google Scholar 

  42. Patrice SJ, Tarbell NJ, Goumnerova LC, et al.: Results of radiosurgery in the management of recurrent and residual medulloblastoma. Pediatr Neurosurg 1995, 22:197–203.

    Article  PubMed  CAS  Google Scholar 

  43. Cangir A, van Eys, Berry DH, et al.: Combination chemotherapy with MOPP in children with recurrent brain tumors. Int J Radiat Oncol Biol Phys 1995, 31:445–451.

    Article  Google Scholar 

  44. Needle MN, Molloy PT, Geyer JR, et al.: Phase II study of daily oral etoposide in children with recurrent brain tumors and other solid tumors. Med Pediatr Oncol 1997, 29:28–32.

    Article  PubMed  CAS  Google Scholar 

  45. Dunkel IJ, Boyett JM: High-dose carboplatin, thiotepa, and etopsoide with autologous stem-cell rescue for patients with recurrent medulloblastoma. J Clin Oncol 1998, 16:222–228.

    PubMed  CAS  Google Scholar 

  46. Walter AW, Mulhern RK, Gajjar, A, et al.: Survival and neurodevelopmental outcome of young children with medulloblastoma at St. Jude Children’s Research Hospital. J Clin Oncol 1999, 17:3720–3728.

    PubMed  CAS  Google Scholar 

  47. Duffner PK, Horowitz ME, Krischer JP, et al.: The treatment of malignant brain tumors in infants and very young children: an update of the Pediatric Oncology Group experience. Neurooncology 1999, 1:152–161.

    CAS  Google Scholar 

  48. Heideman RL: Overview of the treatment of infant central nervous system tumors: medulloblastoma as a model. J Pediatr Hematol Oncol 2001, 23:268–271. This is an excellent review of recent Pediatric Oncology Group and Children’s Cancer Group studies—a comprehensive, concise, and well-presented summary of results.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, University of Pittsburgh Children’s Hospital, 3705 Fifth Avenue, Suite 3705, Third Floor, 15213, Pittsburgh, PA, USA

    Ian F. Pollack MD

Authors
  1. Catherine A. Mazzola MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ian F. Pollack MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mazzola, C.A., Pollack, I.F. Medulloblastoma. Curr Treat Options Neurol 5, 189–198 (2003). https://doi.org/10.1007/s11940-003-0009-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-003-0009-9

Keywords

Search

Navigation